(Indianapolis, IN) – The Indiana Family and Social Services Administration’s Division of Mental Health and Addiction (DHMA) is providing new funding to help build and support projects across the state to improve mental health and recovery services for Hoosiers.
This includes funding from the federal American Rescue Plan Act and the National Opioid Settlement, and totals more than $76 million.
Fifteen community mental health centers across the state are receiving $57 million in Crisis Receiving and Stabilization Services grants.
These grants will support the advancement of an integrated crisis response system that provides Hoosiers experiencing a mental health and/or substance use crisis someone to contact, someone to respond to, and a safe place for help.
Local entities receiving funds are:
- Community Mental Health, Inc., which serves Dearborn, Ripley, Franklin, Ohio, and Switzerland County residents, was awarded $4,970,878 to establish a new, sub-acute Crisis Receiving and Stabilization Services Program to serve youth and adults experiencing a crisis in accordance with SAMHSA Best Practices while implementing a No Wrong Door philosophy.
- Centerstone of Indiana, Inc., which serves residents of Decatur and several other counties, was granted $3,131,161.80 for a similar objective.
You can find more here on the 15 projects funded by the Crisis Receiving and Stabilization Services grants.
As part of the National Opioid Settlement, DMHA, in partnership with the Office of Governor Eric Holcomb, is awarding a total of $19 million in one-time funding to support evidence-based prevention, treatment, recovery, and harm reduction services, expand the behavioral health workforce and implement other services and initiatives across the state, to 30 local units of government, service providers, and community organizations.
The State of Indiana is receiving approximately $507 million over an 18-year period as part of the National Opioid Settlement with distributors McKesson, Cardinal Health, and AmerisourceBergen and manufacturer Janssen Pharmaceuticals, Inc. and its parent company Johnson & Johnson.
